• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correction to: Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing.

作者信息

Eguizabal C, Herrera L, Inglés-Ferrándiz M, Belmonte J C Izpisua

机构信息

Cell Therapy, Stem Cells and Tissues Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.

Research Unit, Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.

出版信息

Stem Cell Res Ther. 2021 Apr 27;12(1):250. doi: 10.1186/s13287-021-02281-1.

DOI:10.1186/s13287-021-02281-1
PMID:33906672
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8080394/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93a/8080394/998415885222/13287_2021_2281_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93a/8080394/1a4e0b31e7e8/13287_2021_2281_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93a/8080394/998415885222/13287_2021_2281_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93a/8080394/1a4e0b31e7e8/13287_2021_2281_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a93a/8080394/998415885222/13287_2021_2281_Fig2_HTML.jpg

相似文献

1
Correction to: Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing.对《治疗自然杀伤细胞缺陷的原发性免疫缺陷：从干细胞治疗到基因编辑》的更正
Stem Cell Res Ther. 2021 Apr 27;12(1):250. doi: 10.1186/s13287-021-02281-1.
2
Novel Genome-Editing Tools to Model and Correct Primary Immunodeficiencies.用于模拟和纠正原发性免疫缺陷的新型基因组编辑工具。
Front Immunol. 2015 May 21;6:250. doi: 10.3389/fimmu.2015.00250. eCollection 2015.
3
Hematopoietic stem cell transplantation for primary lymphoid immunodeficiencies.原发性淋巴细胞免疫缺陷的造血干细胞移植
Semin Hematol. 1998 Oct;35(4):346-53.
4
Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles.人类造血干细胞和祖细胞的基因编辑：前景与潜在障碍
Hum Gene Ther. 2016 Oct;27(10):729-740. doi: 10.1089/hum.2016.107. Epub 2016 Aug 2.
5
Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1.临床前模型突出了造血干细胞基因编辑治疗 X 连锁重症联合免疫缺陷病 1 型的潜力。
Sci Transl Med. 2017 Oct 11;9(411). doi: 10.1126/scitranslmed.aan0820.
6
Molecular Evidence of Genome Editing in a Mouse Model of Immunodeficiency.免疫缺陷小鼠模型中基因组编辑的分子证据。
Sci Rep. 2018 May 29;8(1):8214. doi: 10.1038/s41598-018-26439-9.
7
CRISPR/Cas9 genome editing in human hematopoietic stem cells.CRISPR/Cas9 基因组编辑在人类造血干细胞中的应用。
Nat Protoc. 2018 Feb;13(2):358-376. doi: 10.1038/nprot.2017.143. Epub 2018 Jan 25.
8
Hematopoietic Stem Cell Transplantation for Primary Immunodeficiencies.原发性免疫缺陷的造血干细胞移植
Front Pediatr. 2019 Oct 30;7:445. doi: 10.3389/fped.2019.00445. eCollection 2019.
9
The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation.造血干细胞基因编辑不断变化的格局：迈向Cas9临床转化的一步。
Curr Opin Hematol. 2017 Nov;24(6):481-488. doi: 10.1097/MOH.0000000000000385.
10
Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches.造血干细胞基因治疗：慢病毒和基因编辑方法的最佳应用。
Blood Rev. 2020 Mar;40:100641. doi: 10.1016/j.blre.2019.100641. Epub 2019 Nov 15.

本文引用的文献

1
CRISPR/Cas9 applications in gene therapy for primary immunodeficiency diseases.CRISPR/Cas9在原发性免疫缺陷疾病基因治疗中的应用。
Emerg Top Life Sci. 2019 May 31;3(3):277-287. doi: 10.1042/ETLS20180157.
2
Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing.用 NK 细胞缺陷治疗原发性免疫缺陷：从干细胞治疗到基因编辑。
Stem Cell Res Ther. 2020 Oct 27;11(1):453. doi: 10.1186/s13287-020-01964-5.
3
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.
基因组编辑技术在人类疾病靶向治疗中的应用：机制、进展与展望。
Signal Transduct Target Ther. 2020 Jan 3;5(1):1. doi: 10.1038/s41392-019-0089-y.
4
Gene therapy and genome editing for primary immunodeficiency diseases.原发性免疫缺陷病的基因治疗和基因组编辑
Genes Dis. 2019 Jul 30;7(1):38-51. doi: 10.1016/j.gendis.2019.07.007. eCollection 2020 Mar.
5
An enhanced CRISPR repressor for targeted mammalian gene regulation.一种增强型 CRISPR 抑制剂，用于靶向哺乳动物基因调控。
Nat Methods. 2018 Aug;15(8):611-616. doi: 10.1038/s41592-018-0048-5. Epub 2018 Jul 16.
6
Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34 Hematopoietic Stem and Progenitor Cells.CD34 造血干/祖细胞中基于 CRISPR/Cas9-AAV6 的基因组编辑的全球转录反应。
Mol Ther. 2018 Oct 3;26(10):2431-2442. doi: 10.1016/j.ymthe.2018.06.002. Epub 2018 Jul 11.
7
Enhanced Bacterial Immunity and Mammalian Genome Editing via RNA-Polymerase-Mediated Dislodging of Cas9 from Double-Strand DNA Breaks.通过 RNA 聚合酶介导的从双链 DNA 断裂中置换 Cas9 实现增强的细菌免疫和哺乳动物基因组编辑。
Mol Cell. 2018 Jul 5;71(1):42-55.e8. doi: 10.1016/j.molcel.2018.06.005.
8
Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome.针对 X 连锁高免疫球蛋白 M 综合征的人造血干细胞的位点特异性基因编辑。
Cell Rep. 2018 May 29;23(9):2606-2616. doi: 10.1016/j.celrep.2018.04.103.
9
Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency.用于X连锁重症联合免疫缺陷基因治疗的慢病毒载体的临床前开发
Mol Ther Methods Clin Dev. 2018 Mar 10;9:257-269. doi: 10.1016/j.omtm.2018.03.002. eCollection 2018 Jun 15.
10
Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.利用 CRISPR-Cas9 系统对血友病 B 患者来源的诱导多能干细胞进行靶向基因组编辑。
Stem Cell Res Ther. 2018 Apr 6;9(1):92. doi: 10.1186/s13287-018-0839-8.